Publications

1. Maurer LM, Daley JD, Mukherjee E, Venier RE, Julian CM, Bailey NG, Jacobs MF, Kumar-Sinha C, Raphael H, Periyapatna N, Weiss K, Janeway KA, Mody R, Lucas PC, McAllister-Lucas LM, Bailey KM. BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. Cancer Res Commun. 2022 Apr; 2 (4):220-232 Epub 2022 Apr 20
   View PubMed
2. Lee JL, Ekambaram P, Carleton NM, Hu D, Klei LR, Cai Z, Myers MI, Hubel NE, Covic L, Agnihotri S, Krappmann D, Bornancin F, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC. MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. Mol Cancer Res. 2022 Mar 1; 20 (3):373-386
   View PubMed
3. Lee JY, Ekambaram P, Carleton NM, Hu D, Klei LR, Cai Z, Myers MI, Hubel NE, Covic L, Agnihotri S, Krappmann D, Bornancin F, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC. MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer. Molecular Cancer Research. 2022; 20(3):373-386.
   View PubMed
4. Lee JY, Ekambaram P, Carleton NM, Hu D, Klei LR, Cai Z, Myers MI, Hubel NE, Covic L, Agnihotri S, Krappmann D, Bornancin F, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas. MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer. Molecular Cancer Research. 2022; 20(3):373-386.
   View PubMed
5. Lee JY, Ekambaram P, Carleton NM, Hu D, Klei LR, Cai Z, Myers MI, Hubel NE, Covic L, Agnihotri S, Krappmann D, Bornancin F, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC. MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer. Molecular Cancer Research. 2022; 20(3):373-386.
   View PubMed
6. Kang H, Maurer LM, Smyers M, Klei L, Cheng J, Hu D, Murai MJ, Mady A, Trotta M, Klei HB, Ekambaram P, Nikolovska-Coleska Z, McAllister-Lucas LM, Lucas PC. Discovery of small molecules to disrupt BCL10-MALT1 interaction and target diffuse large B-cell lymphoma J. Clin. Invest.. 2022.
   
7. Abman SH, Armstrong S, Baker S, Bogue CW, Carlo W, Chalak L, Daniels SR, Davis S, Debaun MR, Fike C, Frazer L, Gibson K, Gill M, Glass H, Gordon CM, Goyal M, Hirschhorn J, Holtz L, Hunstad DA, Leonard MB, Maitre N, Markham L, McAllister-Lucas L, Orange J, Shah P, Simon T, Steinhorn RH, Tarini B, Walker-Harding LR. The american pediatric society and society for pediatric research joint statement against racism and social injustice. Pediatr Res. 2022 Jan; 91 (1):72 Epub 2020 Sept 03
   View PubMed
8. Cheng J, Lucas PC, McAllister-Lucas LM. Canonical and Non-Canonical Roles of GRK2 in Lymphocytes. Cells. 2021 Feb 3; 10 (2) Epub 2021 Feb 03
   View PubMed
9. Cheng J, Maurer LM, Kang H, Lucas PC, McAllister-Lucas LM. Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist. Cell Immunol. 2020 Sep; 355:104158 Epub 2020 July 07
   View PubMed
10. Alfano DN, Klei LR, Klei HB, Trotta M, Gough PJ, Foley KP, Bertin J, Sumpter TL, Lucas PC, McAllister-Lucas LM. MALT1 Protease Plays a Dual Role in the Allergic Response by Acting in Both Mast Cells and Endothelial Cells. J Immunol. 2020 May 1; 204 (9):2337-2348 Epub 2020 Mar 25
    View PubMed
11. Cheng J, Klei LR, Hubel NE, Zhang M, Schairer R, Maurer LM, Klei HB, Kang H, Concel VJ, Delekta PC, Dang EV, Mintz MA, Baens M, Cyster JG, Parameswaran N, Thome M, Lucas PC, McAllister-Lucas LM. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J Clin Invest. 2020 Feb 3; 130 (2):1036-1051
    View PubMed
12. McAuley JR, Bailey KM, Ekambaram P, Klei LR, Kang H, Hu D, Freeman TJ, Concel VJ, Hubel NE, Lee JL, Klei HB, Cheng J, Sekar P, Bridwell RE, Covic L, Lucas PC, McAllister-Lucas LM. MALT1 is a critical mediator of PAR1-driven NF-kappaB activation and metastasis in multiple tumor types. Oncogene. 2019 Dec; 38 (49):7384-7398 Epub 2019 Aug 16
    View PubMed
13. McAuley JR, Bailey KM, Ekambaram P, Klei LR, Kang H, Hu D, Freeman TJ, Concel VJ, Hubel NE, Lee JL, Klei HB, Cheng J, Sekar P, Bridwell RE, Covic L, Lucas PC, McAllister-Lucas LM. MALT1 is a critical mediator of PAR1-driven NF-?B activation and metastasis in multiple tumor types. Oncogene. 2019; 38(49):7384-7398.
    View PubMed
14. McAuley JR, Bailey KM, Ekambaram P, Klei LR, Kang H, Hu D, Freeman TJ, Concel VJ, Hubel NE, Lee JL, Klei HB, Cheng J, Sekar P, Bridwell RE, Covic L, Lucas PC, McAllister-Lucas LM. MALT1 is a critical mediator of PAR1-driven NF-?B activation and metastasis in multiple tumor types. Oncogene. 2019; 38(49):7384-7398.
    View PubMed
15. Bailey KM, Julian CM, Klinghoffer AN, Bernard H, Lucas PC, McAllister-Lucas LM. EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis. Oncotarget. 2019 May 21; 10 (36):3385-3399
    View PubMed
16. Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology. 2019; 8 (1):e1512455 Epub 2018 Oct 11
    View PubMed
17. Stanley K, Friehling E, Ranganathan S, Mazariegos G, McAllister-Lucas LM, Sindhi R. Post-transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review. Pediatr Transplant. 2018 Aug; 22 (5):e13211 Epub 2018 May 10
    View PubMed
18. Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC. The CARMA3-Bcl10-MALT1 Signalosome Drives NFkappaB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer Res. 2018 Mar 1; 78 (5):1225-1240 Epub 2017 Dec 19
    View PubMed
19. Ekambaram P, Lee J-Y, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC. The CARMA3-Bcl10-MALT1 Signalosome Drives NF-?B Activation and Aggressive Phenotype in AGTR1-positive Breast Cancer. Cancer Research. 2018; 78(5):1225-1240.
    View PubMed
20. Ekambaram P, Lee, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC. The CARMA3-Bcl10-MALT1 Signalosome Drives NF-?B Activation and Aggressive Phenotype in AGTR1-positive Breast Cancer. Cancer Research. 2018; 78(5):1225-1240.
    View PubMed
21. McAuley JR, Freeman TJ, Ekambaram P, Lucas PC, McAllister-Lucas LM. CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis. Front Immunol. 2018; 9:1887 Epub 2018 Aug 15
    View PubMed
22. Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, Oravecz-Wilson KI, Concel VJ, Hess EM, Van Beek M, Delekta PC, Gu S, Watkins SC, Ting AT, Gough PJ, Foley KP, Bertin J, McAllister-Lucas LM, Lucas PC. MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage. Cell Rep. 2016 Sep 27; 17 (1):221-232
    View PubMed
23. Klei LR, Hu D, Panek R, Alfano D, Bridwell R, Bailey K, Oravecz-Wilson K, Concel V, Van M, Delekta P, Gu S, Watkins S, Ting A, Gough P, Foley K, Bertin J, McAllister-Lucas L, Lucas PC. MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. Cell Reports. 2016; 17(1):221-232.
    View PubMed
24. Klei LR, Hu D, Panek R, Alfano D, Bridwell R, Bailey K, Oravecz-Wilson K, Concel V, Van M, Delekta P, Gu S, Watkins S, Ting A, Gough P, Foley K, Bertin J, McAllister-Lucas L, Lucas PC. MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. Cell Reports. 2016; 17(1):221-232.
    View PubMed
25. Klei LR, Hu D, Panek R, Alfano D, Bridwell R, Bailey K, Oravecz-Wilson K, Concel V, Van M, Delekta P, Gu S, Watkins S, Ting A, Gough P, Foley K, Bertin J, McAllister-Lucas L, Lucas PC. MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. Cancer Research. 2016; 17(1):221-232.
    View PubMed
26. Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC. API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis. World J Biol Chem. 2016 Feb 26; 7 (1):128-37
    View PubMed
27. Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, Lim MS, Elenitoba-Johnson KS. Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma. Nat Commun. 2015 Jan 8; 6:5908 Epub 2015 Jan 08
    View PubMed
28. Marko L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Muller DN. Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling. Hypertension. 2014 Nov; 64 (5):1032-9 Epub 2014 Sept 02
    View PubMed
29. Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM. The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-kappaB signaling. Oncogene. 2014 May 8; 33 (19):2520-30 Epub 2013 June 17
    View PubMed
30. Shukla N, Kobos R, Renaud T, Teruya-Feldstein J, Price A, McAllister-Lucas L, Steinherz P. Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer. 2012 Aug 1; 118 (15):3719-24 Epub 2011 Dec 13
    View PubMed
31. Bailey KM, Castle VP, Hummel JM, Piert M, Moyer J, McAllister-Lucas LM. Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. J Pediatr Hematol Oncol. 2012 Aug; 34 (6):480-3
    View PubMed
32. Van Beek M, Oravecz-Wilson KI, Delekta PC, Gu S, Li X, Jin X, Apel IJ, Konkle KS, Feng Y, Teitelbaum DH, Ruland J, McAllister-Lucas LM, Lucas PC. Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance. Cell Rep. 2012 May 31; 1 (5):444-52
    View PubMed
33. Chen A, Vander Lugt M, McAllister-Lucas LM, Killen PD, Blatt NB. An unusual case of membranous nephropathy associated with an ovarian tumor. Pediatr Nephrol. 2011 Dec; 26 (12):2249-51 Epub 2011 Sept 04
    View PubMed
34. McAllister-Lucas LM, Baens M, Lucas PC. MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res. 2011 Nov 1; 17 (21):6623-31 Epub 2011 Aug 25
    View PubMed
35. Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM. From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle. 2011 Aug 1; 10 (15):2485-96 Epub 2011 Aug 01
    View PubMed
36. Rosebeck S, Lucas PC, McAllister-Lucas LM. Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol. 2011 May; 7 (5):613-7
    View PubMed
37. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science. 2011 Jan 28; 331 (6016):468-72
    View PubMed
38. Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC. Thrombin-dependent NF-kappaB activation and monocyte/endothelial adhesion are mediated by the CARMA3.Bcl10.MALT1 signalosome. J Biol Chem. 2010 Dec 31; 285 (53):41432-42 Epub 2010 Nov 01
    View PubMed
39. McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, Delekta PC, Van Beek M, Lucas PC. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem. 2010 Aug 20; 285 (34):25880-4 Epub 2010 July 05
    View PubMed
40. Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J, McAllister-Lucas LM. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene. 2007 Aug 16; 26 (38):5643-54 Epub 2007 Mar 05
    View PubMed
41. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nunez G, Lucas PC. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A. 2007 Jan 2; 104 (1):139-44 Epub 2006 Nov 13
    View PubMed
42. Lucas PC, McAllister-Lucas LM, Nunez G. NF-kappaB signaling in lymphocytes: a new cast of characters. J Cell Sci. 2004 Jan 1; 117 (Pt 1):31-9
    View PubMed
43. Thornburg CD, Shulkin BL, Castle VP, McAllister-Lucas LM. Thoracic neural crest tumors in Beckwith-Wiedemann syndrome. Med Pediatr Oncol. 2003 Nov; 41 (5):468-9
    View PubMed
44. Wang D, You Y, Case SM, McAllister-Lucas LM, Wang L, DiStefano PS, Nunez G, Bertin J, Lin X. A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol. 2002 Sep; 3 (9):830-5 Epub 2002 Aug 05
    View PubMed
45. Muto A, Ruland J, McAllister-Lucas LM, Lucas PC, Yamaoka S, Chen FF, Lin A, Mak TW, Nunez G, Inohara N. Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester. J Biol Chem. 2002 Aug 30; 277 (35):31871-6 Epub 2002 June 28
    View PubMed
46. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW Jr. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem. 2001 Dec 28; 276 (52):48921-9 Epub 2001 Oct 25
    View PubMed
47. McAllister-Lucas LM, Inohara N, Lucas PC, Ruland J, Benito A, Li Q, Chen S, Chen FF, Yamaoka S, Verma IM, Mak TW, Nunez G. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction. J Biol Chem. 2001 Aug 17; 276 (33):30589-97 Epub 2001 May 31
    View PubMed
48. Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, Yamaoka S, Seto M, Nunez G. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem. 2001 Jun 1; 276 (22):19012-9 Epub 2001 Mar 21
    View PubMed
49. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene. 1998 Aug 17; 216 (1):139-47
    View PubMed
50. Turko IV, Haik TL, McAllister-Lucas LM, Burns F, Francis SH, Corbin JD. Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. J Biol Chem. 1996 Sep 6; 271 (36):22240-4
    View PubMed
51. McAllister-Lucas LM, Haik TL, Colbran JL, Sonnenburg WK, Seger D, Turko IV, Beavo JA, Francis SH, Corbin JD. An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J Biol Chem. 1995 Dec 22; 270 (51):30671-9
    View PubMed
52. Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD. Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem. 1994 Sep 9; 269 (36):22477-80
    View PubMed
53. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, Trong HL, Colbran JL, Thomas MK, Walsh KA, Francis SH, Corbin JD. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem. 1993 Oct 25; 268 (30):22863-73
    View PubMed
54. Corbin JD, Woodall CC, Colbran JL, McAllister LM, Sekhar KR, Francis SH. Identifying protein kinases in crude extracts that phosphorylate cyclic GMP-binding cyclic-GMP specific phosphodiesterase. Agents Actions Suppl. 1993; 43:27-33
    View PubMed
55. Colbran JL, Francis SH, Leach AB, Thomas MK, Jiang H, McAllister LM, Corbin JD. A phenylalanine in peptide substrates provides for selectivity between cGMP- and cAMP-dependent protein kinases. J Biol Chem. 1992 May 15; 267 (14):9589-94
    View PubMed
56. Buffington LA, Blackburn DW, Hamilton CL, Jarvis JJ, Knowles JJ, Lodwick PA, McAllister LM, Neidhart DJ, Serumgard JL. Effects of solvent and anomeric configuration upon the circular dichroism, temperature dependence of amide proton chemical shifts, amide proton exchange rates, and infrared absorption of methyl 2-acetamido-2-deoxy-Dglucopyranosides J. Amer. Chem. Soc.. 1987; 111:2451-2454.